Source link : https://news7.asia/health/icis-associated-with-twofold-increased-psoriasis-risk/
TOPLINE:Patients with cancer who receive immune checkpoint inhibitors (ICIs) have more than twice the risk for developing psoriasis compared with those who receive other treatments.
METHODOLOGY:Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan Cancer Registry.A total of 135,230 patients with clinical stage III or IV cancer (mean age, 62.94 years; 45.1% women) who received antineoplastic medications between January 2019 and June 2021 were included in the study.Patients were classified as ICI users (n=3188) and those who received chemotherapy or targeted therapies were classified as non-ICI users (n=132,042).The primary outcome was the incidence of psoriasis during the follow-up period. The mean follow-up duration was 1.46 years.TAKEAWAY:A total of 295 patients (0.2%) were diagnosed with psoriasis. ICI users experienced a higher incidence of psoriasis than non-ICI users (5.76 vs 1.44 cases per 1000 person-years).Those treated with ICIs had more than a threefold increase in the risk for psoriasis after adjusting for demographic factors and comorbidities (hazard ratio [HR], 3.31; P
Source : Medscape
Author : News7
Publish date : 2024-11-07 01:00:00
Copyright for syndicated content belongs to the linked Source.